Transmission-blocking potential of novel HIV Env-specific mucosal antibodies
新型 HIV Env 特异性粘膜抗体的传播阻断潜力
基本信息
- 批准号:9267899
- 负责人:
- 金额:$ 60.21万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2013
- 资助国家:美国
- 起止时间:2013-05-22 至 2019-04-30
- 项目状态:已结题
- 来源:
- 关键词:AntibodiesAntibody ResponseAntiviral AgentsB-LymphocytesBloodBreast FeedingBreastfed infantCell SeparationCellsCharacteristicsChronicColostrumDendritic CellsDevelopmentEpitopesEventGeneticGoalsGrowthGut associated lymphoid tissueHIVHIV-1HIV-1 vaccineHome environmentHuman MilkImmune responseImmunizationImmunoglobulin AImmunoglobulin GImmunoglobulin GenesIn VitroInfantInfectionInvestigationLactationMacaca mulattaMammary glandMaternal antibodyMediatingMilkModelingMonoclonal AntibodiesMucous MembraneNeonatalOralPeripheralPeripheral Blood Mononuclear CellPlasmaPopulationProductionRecombinantsRoleSourceSpecificitySurfaceTechniquesTechnologyVaccinationVaccine DesignVaccinesViralViral PhysiologyVirionVirusWomanWorkantibody-dependent cell cytotoxicitybasedesigngastrointestinalin vitro Assayin vivomucosal siteneutralizing antibodynovelpathogenperipheral bloodpostnatalpreventpublic health relevancerepositoryresponsesimian human immunodeficiency virustransmission processvaccine developmentvaccine trialviral transmission
项目摘要
DESCRIPTION: A successful HIV-1 vaccine must elicit immune responses that impede virus transmission at mucosal sites of virus exposure. However, HIV-1 vaccine development is hampered by a lack of understanding of the epitope-specificity and functional role of HIV-1 Envelope (Env)-specific antibodies produced by mucosal B cell populations. The goal of this proposal is to determine the ability of naturally-elicited mucosal antibodies to block mucosal HIV-1 transmission. Breast milk is a rich source of mucosal antibodies which represent the ontogeny of the gastrointestinal B cell population (the "gut-mammary axis"). Moreover, these mucosal antibodies may contribute to passive protection against HIV-1 acquisition in the majority of HIV-1-exposed, breastfed infants. We recently established the technology required for isolation of HIV-1 Env-specific B cells and recombinant production of their monoclonal antibodies (mAbs) from colostrum of HIV-infected, lactating women. Using this technique, we isolated novel HIV-1 Env-specific mucosal IgG and IgA antibodies from breast milk B cells, and demonstrated their neutralizing and nonneutralizing functions. As mucosal B cell responses are compartmentalized from those in peripheral blood, we hypothesize that the repertoire of HIV-1 Env-specific-IgG/IgA antibodies isolated from mammary B cells are genetically and functionally distinct to those isolated from peripheral B cells. In this proposal, we will 1) contrast the genetc characteristics and epitope-specificity of HIV-1 Env-specific antibodies produced by systemic and mucosal B cells isolated from a repository of breast milk and peripheral blood mononuclear cells of HIV-1-infected women; 2) identify qualities and epitope-specificities of mucosal HIV-1 Env-specific IgG and IgA antibodies that possess potent in vitro neutralizing and nonneutralizing functions that may block HIV-1 transmission; and 3) determine the ability of mucosally-produced HIV Env-specific IgG and IgA antibodies to protect against virus acquisition in vivo, using the neonatal rhesus monkey/oral simian-HIV (SHIV) transmission model. This work will set the standard for the type of mucosal antibody responses that an effective HIV-1 vaccine should target. Moreover, our work will define the mucosal HIV-1 Env-specific IgG and IgA antibody responses that can protect against HIV-1 transmission to infants via breastfeeding, establishing the maternal antibody responses required to eliminate postnatal HIV-1 transmission.
描述:成功的HIV-1疫苗必须引起免疫反应,这会阻碍病毒暴露的粘膜部位传播。然而,由于缺乏对粘膜B细胞群体产生的HIV-1 Invelope(ENK)特异性抗体的表位特异性和功能作用的了解,HIV-1疫苗的发育受到阻碍。该提案的目的是确定自然吸收的粘膜抗体阻断粘膜HIV-1传播的能力。母乳是粘膜抗体的丰富来源,代表胃肠道B细胞种群的个体发育(“肠乳腺轴”)。此外,这些粘膜抗体可能有助于在大多数暴露于HIV-1的母乳喂养婴儿中对HIV-1获取的被动保护。我们最近建立了分离HIV-1 ENV特异性B细胞的技术,并从HIV感染的哺乳期妇女的初乳中重组产生其单克隆抗体(MAB)。使用这种技术,我们从母乳B细胞中分离了新型的HIV-1 Env特异性粘膜IgG和IgA抗体,并证明了它们中和和非中和化功能。由于粘膜B细胞反应是从外周血中的粘膜B细胞反应分隔的,因此我们假设从乳腺B细胞中分离出的HIV-1 ENV特异性-IGG/IGA抗体的曲目在遗传上和功能上与与外周B细胞分离的曲线在功能上与众不同。在此提案中,我们将1)对比由从母乳和外周血血液单核细胞中分离出的HIV-1和粘膜B细胞产生的HIV-1 ENV特异性抗体的遗传学特征和表位特异性; 2)确定粘膜HIV-1 ENV特异性IgG和IgA抗体的质量和表位特异性,这些抗体具有有效的体外中和和非中和化功能,这些功能可能阻止HIV-1传播; 3)确定使用新生儿恒河猴/口腔猴子-HIV(SHIV)透射模型,确定粘液生产的HIV ENV特异性IgG和IgA抗体预防体内病毒的能力。这项工作将为有效的HIV-1疫苗应针对的粘膜抗体反应类型设定标准。此外,我们的工作将定义粘膜HIV-1 ENV特异性IgG和IgA抗体反应,这些反应可以通过母乳喂养来防止HIV-1向婴儿传播,从而确定消除产后HIV-1传播所需的母体抗体反应。
项目成果
期刊论文数量(1)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Predominant envelope variable loop 2-specific and gp120-specific antibody-dependent cellular cytotoxicity antibody responses in acutely SIV-infected African green monkeys.
- DOI:10.1186/s12977-018-0406-5
- 发表时间:2018-03-09
- 期刊:
- 影响因子:3.3
- 作者:Nguyen QN;Martinez DR;Himes JE;Whitney Edwards R;Han Q;Kumar A;Mangan R;Nicely NI;Xie G;Vandergrift N;Shen X;Pollara J;Permar SR
- 通讯作者:Permar SR
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Sallie R. Permar其他文献
Sallie R. Permar的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Sallie R. Permar', 18)}}的其他基金
Identifying and modeling immune correlates of protection against congenital CMV transmission after primary maternal infection
原发性母体感染后预防先天性巨细胞病毒传播的免疫相关性的识别和建模
- 批准号:
10677439 - 财政年份:2023
- 资助金额:
$ 60.21万 - 项目类别:
Escape of maternal plasma broadly neutralizing antibody as a mechanism of mother to child HIV transmission
母体血浆广泛中和抗体的逃逸是艾滋病毒母婴传播的机制
- 批准号:
10327003 - 财政年份:2021
- 资助金额:
$ 60.21万 - 项目类别:
Immunogenicity and Efficacy of SARS-CoV-2 stabilized prefusion Spike protein vaccines in infant rhesus macaques
SARS-CoV-2 稳定预灌注 Spike 蛋白疫苗在幼年恒河猴中的免疫原性和功效
- 批准号:
10223633 - 财政年份:2020
- 资助金额:
$ 60.21万 - 项目类别:
相似国自然基金
B7H4-LILRB4信号调控B细胞代谢重编程机制在同种抗体产生及防治AMR中的作用
- 批准号:82371792
- 批准年份:2023
- 资助金额:49.00 万元
- 项目类别:面上项目
抗变构/单体形式的C反应蛋白关键抗原表位199-206抗体在狼疮性肾炎小管间质病变中的作用机制及其靶向治疗研究
- 批准号:82300829
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
TSC1对滤泡辅助性T细胞在抗体介导的排斥反应中的调控作用及其机制研究
- 批准号:82370760
- 批准年份:2023
- 资助金额:49 万元
- 项目类别:面上项目
抗BP180抗体活化基底层角质形成细胞中Fn14-TRAF2-ZFP36轴促进大疱性类天疱疮炎症反应的机制探究
- 批准号:82373476
- 批准年份:2023
- 资助金额:49 万元
- 项目类别:面上项目
NK细胞靶向微泡超声分子成像评价抗体介导排斥反应的研究
- 批准号:82302225
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
相似海外基金
Host Defense Small Molecule Development for COVID-19 Treatment by Targeting Lysosome
通过靶向溶酶体治疗 COVID-19 的宿主防御小分子开发
- 批准号:
10735492 - 财政年份:2023
- 资助金额:
$ 60.21万 - 项目类别:
Broadly neutralizing SARS-CoV-2 peptidic knobs
广泛中和 SARS-CoV-2 肽旋钮
- 批准号:
10735902 - 财政年份:2023
- 资助金额:
$ 60.21万 - 项目类别:
Development of rotavirus-based enterotoxigenic Escherichia coli dual vaccines
基于轮状病毒的产肠毒素大肠杆菌双重疫苗的研制
- 批准号:
10741541 - 财政年份:2023
- 资助金额:
$ 60.21万 - 项目类别:
First-in-human study of a potent anti-HBsAg neutralizing antibody
强效抗 HBsAg 中和抗体的首次人体研究
- 批准号:
10550458 - 财政年份:2023
- 资助金额:
$ 60.21万 - 项目类别:
Molecular and structural characterization of broadly neutralizing anti-HCV antibodies
广泛中和抗 HCV 抗体的分子和结构表征
- 批准号:
10657917 - 财政年份:2023
- 资助金额:
$ 60.21万 - 项目类别: